vs

Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and STANDARD MOTOR PRODUCTS, INC. (SMP). Click either name above to swap in a different company.

STANDARD MOTOR PRODUCTS, INC. is the larger business by last-quarter revenue ($385.1M vs $196.9M, roughly 2.0× Pacira BioSciences, Inc.). On growth, STANDARD MOTOR PRODUCTS, INC. posted the faster year-over-year revenue change (12.2% vs 5.1%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $-37.6M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs 7.8%).

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.

Standard Motor Products, Inc. is a manufacturer and distributor of automotive parts. The company was founded in 1919 as a partnership by Elias Fife and Ralph Van Allen and incorporated by Fife in 1926. It is headquartered in Long Island City, New York, and trades on the New York Stock Exchange. SMP includes four operational segments: Vehicle Control, Temperature Control, Engineered Solutions and Nissens. SMP’s Vehicle Control and Temperature Control divisions supply automotive aftermarket com...

PCRX vs SMP — Head-to-Head

Bigger by revenue
SMP
SMP
2.0× larger
SMP
$385.1M
$196.9M
PCRX
Growing faster (revenue YoY)
SMP
SMP
+7.0% gap
SMP
12.2%
5.1%
PCRX
More free cash flow
PCRX
PCRX
$81.1M more FCF
PCRX
$43.5M
$-37.6M
SMP
Faster 2-yr revenue CAGR
PCRX
PCRX
Annualised
PCRX
8.5%
7.8%
SMP

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PCRX
PCRX
SMP
SMP
Revenue
$196.9M
$385.1M
Net Profit
$7.9M
Gross Margin
79.5%
31.7%
Operating Margin
1.2%
5.6%
Net Margin
2.0%
Revenue YoY
5.1%
12.2%
Net Profit YoY
457.9%
EPS (diluted)
$0.05
$0.34

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PCRX
PCRX
SMP
SMP
Q4 25
$196.9M
$385.1M
Q3 25
$179.5M
$498.8M
Q2 25
$181.1M
$493.9M
Q1 25
$168.9M
$413.4M
Q4 24
$187.3M
$343.4M
Q3 24
$168.6M
$399.3M
Q2 24
$178.0M
$389.8M
Q1 24
$167.1M
$331.4M
Net Profit
PCRX
PCRX
SMP
SMP
Q4 25
$7.9M
Q3 25
$5.4M
$-4.3M
Q2 25
$-4.8M
$25.2M
Q1 25
$4.8M
$12.6M
Q4 24
$-2.2M
Q3 24
$-143.5M
$3.8M
Q2 24
$18.9M
$17.1M
Q1 24
$9.0M
$8.8M
Gross Margin
PCRX
PCRX
SMP
SMP
Q4 25
79.5%
31.7%
Q3 25
80.9%
32.4%
Q2 25
77.4%
30.6%
Q1 25
79.7%
30.2%
Q4 24
78.7%
29.4%
Q3 24
76.9%
30.4%
Q2 24
75.1%
28.6%
Q1 24
71.6%
27.0%
Operating Margin
PCRX
PCRX
SMP
SMP
Q4 25
1.2%
5.6%
Q3 25
3.5%
9.5%
Q2 25
4.7%
8.7%
Q1 25
1.2%
5.9%
Q4 24
13.2%
1.1%
Q3 24
-82.8%
9.3%
Q2 24
15.9%
6.4%
Q1 24
7.9%
4.4%
Net Margin
PCRX
PCRX
SMP
SMP
Q4 25
2.0%
Q3 25
3.0%
-0.9%
Q2 25
-2.7%
5.1%
Q1 25
2.8%
3.0%
Q4 24
-0.6%
Q3 24
-85.1%
1.0%
Q2 24
10.6%
4.4%
Q1 24
5.4%
2.7%
EPS (diluted)
PCRX
PCRX
SMP
SMP
Q4 25
$0.05
$0.34
Q3 25
$0.12
$-0.19
Q2 25
$-0.11
$1.13
Q1 25
$0.10
$0.56
Q4 24
$0.38
$-0.09
Q3 24
$-3.11
$0.17
Q2 24
$0.39
$0.77
Q1 24
$0.19
$0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PCRX
PCRX
SMP
SMP
Cash + ST InvestmentsLiquidity on hand
$238.4M
Total DebtLower is stronger
$372.2M
$618.7M
Stockholders' EquityBook value
$693.1M
$683.7M
Total Assets
$1.3B
$2.0B
Debt / EquityLower = less leverage
0.54×
0.90×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PCRX
PCRX
SMP
SMP
Q4 25
$238.4M
Q3 25
$246.3M
$87.2M
Q2 25
$445.9M
$58.8M
Q1 25
$493.6M
$50.3M
Q4 24
$484.6M
$44.4M
Q3 24
$453.8M
$26.3M
Q2 24
$404.2M
$26.2M
Q1 24
$325.9M
$27.1M
Total Debt
PCRX
PCRX
SMP
SMP
Q4 25
$372.2M
$618.7M
Q3 25
$376.7M
$589.5M
Q2 25
$580.5M
$636.6M
Q1 25
$583.4M
$650.6M
Q4 24
$585.3M
$562.3M
Q3 24
$142.8M
Q2 24
$208.2M
Q1 24
$214.9M
Stockholders' Equity
PCRX
PCRX
SMP
SMP
Q4 25
$693.1M
$683.7M
Q3 25
$727.2M
$677.4M
Q2 25
$757.8M
$688.6M
Q1 25
$798.5M
$638.0M
Q4 24
$778.3M
$615.7M
Q3 24
$749.6M
$638.8M
Q2 24
$879.3M
$640.0M
Q1 24
$892.2M
$639.1M
Total Assets
PCRX
PCRX
SMP
SMP
Q4 25
$1.3B
$2.0B
Q3 25
$1.3B
$2.0B
Q2 25
$1.5B
$2.0B
Q1 25
$1.6B
$1.9B
Q4 24
$1.6B
$1.8B
Q3 24
$1.5B
$1.4B
Q2 24
$1.6B
$1.4B
Q1 24
$1.6B
$1.4B
Debt / Equity
PCRX
PCRX
SMP
SMP
Q4 25
0.54×
0.90×
Q3 25
0.52×
0.87×
Q2 25
0.77×
0.92×
Q1 25
0.73×
1.02×
Q4 24
0.75×
0.91×
Q3 24
0.22×
Q2 24
0.33×
Q1 24
0.34×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PCRX
PCRX
SMP
SMP
Operating Cash FlowLast quarter
$43.7M
$-28.2M
Free Cash FlowOCF − Capex
$43.5M
$-37.6M
FCF MarginFCF / Revenue
22.1%
-9.8%
Capex IntensityCapex / Revenue
0.1%
2.4%
Cash ConversionOCF / Net Profit
-3.59×
TTM Free Cash FlowTrailing 4 quarters
$136.7M
$18.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PCRX
PCRX
SMP
SMP
Q4 25
$43.7M
$-28.2M
Q3 25
$60.8M
$91.6M
Q2 25
$12.0M
$54.3M
Q1 25
$35.5M
$-60.2M
Q4 24
$33.1M
$-1.5M
Q3 24
$53.9M
$88.3M
Q2 24
$53.2M
$35.6M
Q1 24
$49.1M
$-45.7M
Free Cash Flow
PCRX
PCRX
SMP
SMP
Q4 25
$43.5M
$-37.6M
Q3 25
$57.0M
$81.5M
Q2 25
$9.3M
$44.2M
Q1 25
$26.9M
$-69.4M
Q4 24
$31.0M
$-11.4M
Q3 24
$49.8M
$77.1M
Q2 24
$51.6M
$22.7M
Q1 24
$46.3M
$-55.8M
FCF Margin
PCRX
PCRX
SMP
SMP
Q4 25
22.1%
-9.8%
Q3 25
31.7%
16.3%
Q2 25
5.1%
8.9%
Q1 25
15.9%
-16.8%
Q4 24
16.6%
-3.3%
Q3 24
29.6%
19.3%
Q2 24
29.0%
5.8%
Q1 24
27.7%
-16.8%
Capex Intensity
PCRX
PCRX
SMP
SMP
Q4 25
0.1%
2.4%
Q3 25
2.2%
2.0%
Q2 25
1.5%
2.1%
Q1 25
5.1%
2.2%
Q4 24
1.1%
2.9%
Q3 24
2.4%
2.8%
Q2 24
0.9%
3.3%
Q1 24
1.7%
3.0%
Cash Conversion
PCRX
PCRX
SMP
SMP
Q4 25
-3.59×
Q3 25
11.20×
Q2 25
2.15×
Q1 25
7.37×
-4.79×
Q4 24
Q3 24
23.19×
Q2 24
2.82×
2.09×
Q1 24
5.47×
-5.18×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PCRX
PCRX

EXPAREL$155.8M79%
ZILRETTA$33.0M17%
Iovera$7.0M4%

SMP
SMP

Engineered Solutions$66.1M17%
Electrical And Safety$63.6M17%
Temperature Control$61.5M16%
Europe Excluding Poland$55.5M14%
Other Thermal Components$30.7M8%
Air Conditioning$22.7M6%
Commercial Vehicle$19.7M5%
All Other$18.9M5%
PL$16.0M4%
Wire Sets And Other$11.9M3%
Engine Efficiency$10.0M3%
Construction Agriculture$7.8M2%

Related Comparisons